

REMARKS

Claims 1-8, 10-12 and 14-26 are presented herein for examination. Various claims have been amended above, primarily for eliminating multiple dependencies and placing the subject matter in better condition for U.S. examination. These amendments have not been made in view of the prior art. The specification has been amended to reflect the priority of the application. Claims 9 and 13 have been canceled as they are directed to non-statutory subject matter. Claims 15-26 are newly added. Examination on the merits is respectfully requested, as is entry of this amendment prior to calculation of the filing fee.

Respectfully submitted,

Date: April 29, 2005



Robert J. Smith
Reg. No. 40,820
Attorney for Applicants

GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
PO Box 13398
Research Triangle Park, NC 27709-3398
Direct Phone (919)483-9616
Facsimile (919)483-7988